Diabetic foot ulcer is a common condition in diabetic patients, which may lead to amputation of the leg. People who rely on insulin for the treatment of diabetes are at high risk of developing a foot ulcer. Moreover, people suffering from diabetes-related kidney, eye, and heart disease and obesity can also suffer from diabetic foot ulcers. The risk of the disease is high in those consuming alcohol and tobacco. The common initial symptoms of diabetic foot ulcer include unusual swelling, redness, irritation, and stenches on one or both feet. Diabetic foot ulcer treatment, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy.
Market Dynamics
Key players operating in the global diabetic foot ulcer treatment market are focusing on adoption of growth strategies such as product launches and regulatory approvals, which are expected to drive the market growth during the forecast period. For instance, in November 2019, Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden-based biopharmaceutical company, received a patent in the U.S. for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers. Moreover, in December 2019, Orpyx Medical Technologies Inc., a medical device company that designs and develops sensory insole systems for the treatment of diabetic foot ulcers, launched Orpyx SI Sensory Insoles with for the prevention of diabetic foot ulcers and neuropathy-related ulcers. Furthermore, in December 2017, SANUWAVE Health Inc., received the US approval for marketing of the Dermapace system, the indicated to treat diabetic foot ulcer.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook